nodes	percent_of_prediction	percent_of_DWPC	metapath
Bevantolol—ADRB2—prostate cancer	0.935	1	CbGaD
Bevantolol—Carvedilol—GJA1—prostate cancer	0.00214	0.159	CrCbGaD
Bevantolol—Carvedilol—HIF1A—prostate cancer	0.00162	0.121	CrCbGaD
Bevantolol—Esmolol—ADRB2—prostate cancer	0.000814	0.0606	CrCbGaD
Bevantolol—Verapamil—CYP2C18—prostate cancer	0.000813	0.0606	CrCbGaD
Bevantolol—Bisoprolol—ADRB2—prostate cancer	0.000692	0.0516	CrCbGaD
Bevantolol—Verapamil—SLC22A1—prostate cancer	0.000664	0.0494	CrCbGaD
Bevantolol—Carvedilol—VEGFA—prostate cancer	0.000653	0.0486	CrCbGaD
Bevantolol—Metoprolol—ADRB2—prostate cancer	0.000554	0.0412	CrCbGaD
Bevantolol—Verapamil—CYP3A5—prostate cancer	0.000536	0.0399	CrCbGaD
Bevantolol—Metoprolol—CYP2C19—prostate cancer	0.000477	0.0355	CrCbGaD
Bevantolol—Ranolazine—CYP3A4—prostate cancer	0.000408	0.0304	CrCbGaD
Bevantolol—Tamsulosin—CYP3A4—prostate cancer	0.000392	0.0292	CrCbGaD
Bevantolol—Bisoprolol—CYP3A4—prostate cancer	0.000379	0.0282	CrCbGaD
Bevantolol—Carvedilol—ADRB2—prostate cancer	0.000367	0.0274	CrCbGaD
Bevantolol—Verapamil—CYP2C19—prostate cancer	0.000365	0.0272	CrCbGaD
Bevantolol—Propranolol—CYP3A5—prostate cancer	0.000353	0.0263	CrCbGaD
Bevantolol—Carvedilol—CYP2E1—prostate cancer	0.000319	0.0238	CrCbGaD
Bevantolol—Carvedilol—CYP1A1—prostate cancer	0.000315	0.0235	CrCbGaD
Bevantolol—Propranolol—ADRB2—prostate cancer	0.000279	0.0208	CrCbGaD
Bevantolol—Propranolol—CYP2C19—prostate cancer	0.000241	0.0179	CrCbGaD
Bevantolol—Propranolol—CYP1A1—prostate cancer	0.00024	0.0178	CrCbGaD
Bevantolol—Verapamil—CYP3A4—prostate cancer	0.000232	0.0173	CrCbGaD
Bevantolol—Propafenone—CYP3A4—prostate cancer	0.000223	0.0166	CrCbGaD
Bevantolol—Carvedilol—CYP3A4—prostate cancer	0.000201	0.015	CrCbGaD
Bevantolol—Propranolol—CYP3A4—prostate cancer	0.000153	0.0114	CrCbGaD
Bevantolol—ADRB2—Signaling Pathways—CXCL12—prostate cancer	2.05e-05	0.000397	CbGpPWpGaD
Bevantolol—ADRB1—Signaling by GPCR—PIK3CG—prostate cancer	1.99e-05	0.000386	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—CASP9—prostate cancer	1.97e-05	0.000382	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—TGFBR1—prostate cancer	1.97e-05	0.000381	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—PTHLH—prostate cancer	1.97e-05	0.000381	CbGpPWpGaD
Bevantolol—ADRB2—Signaling by GPCR—PIK3CG—prostate cancer	1.95e-05	0.000378	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—AKR1C3—prostate cancer	1.94e-05	0.000375	CbGpPWpGaD
Bevantolol—ADRB1—GPCR downstream signaling—PIK3CD—prostate cancer	1.93e-05	0.000374	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—CASP9—prostate cancer	1.93e-05	0.000373	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—PRKACB—prostate cancer	1.93e-05	0.000373	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—PRKCQ—prostate cancer	1.91e-05	0.00037	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—NGFR—prostate cancer	1.91e-05	0.00037	CbGpPWpGaD
Bevantolol—ADRB2—GPCR downstream signaling—PIK3CD—prostate cancer	1.89e-05	0.000366	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—MAP3K7—prostate cancer	1.89e-05	0.000365	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—THBS1—prostate cancer	1.88e-05	0.000364	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—PPP3CA—prostate cancer	1.88e-05	0.000364	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—PRKCQ—prostate cancer	1.87e-05	0.000362	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—NGFR—prostate cancer	1.87e-05	0.000362	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—ANXA1—prostate cancer	1.85e-05	0.000359	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—MAP3K7—prostate cancer	1.85e-05	0.000358	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—PRKCZ—prostate cancer	1.82e-05	0.000352	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—FGF10—prostate cancer	1.81e-05	0.000351	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—ADRB2—prostate cancer	1.79e-05	0.000348	CbGpPWpGaD
Bevantolol—ADRA1A—GPCR downstream signaling—PIK3CG—prostate cancer	1.78e-05	0.000344	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—FGF10—prostate cancer	1.77e-05	0.000344	CbGpPWpGaD
Bevantolol—ADRB1—GPCR downstream signaling—JAK2—prostate cancer	1.77e-05	0.000343	CbGpPWpGaD
Bevantolol—ADRB1—Signaling by GPCR—MAP2K1—prostate cancer	1.76e-05	0.000342	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—PARP1—prostate cancer	1.75e-05	0.00034	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—FGFR4—prostate cancer	1.75e-05	0.00034	CbGpPWpGaD
Bevantolol—ADRB1—Signaling by GPCR—PIK3CD—prostate cancer	1.75e-05	0.000339	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—VAV3—prostate cancer	1.75e-05	0.000339	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—CALCA—prostate cancer	1.73e-05	0.000336	CbGpPWpGaD
Bevantolol—ADRB2—GPCR downstream signaling—JAK2—prostate cancer	1.73e-05	0.000336	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—TGFBR2—prostate cancer	1.73e-05	0.000334	CbGpPWpGaD
Bevantolol—ADRB2—Signaling by GPCR—MAP2K1—prostate cancer	1.73e-05	0.000334	CbGpPWpGaD
Bevantolol—ADRB2—Signaling by GPCR—PIK3CD—prostate cancer	1.71e-05	0.000332	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—VAV3—prostate cancer	1.71e-05	0.000332	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—ITPR1—prostate cancer	1.7e-05	0.000329	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—CXCL12—prostate cancer	1.69e-05	0.000328	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—TGFBR2—prostate cancer	1.69e-05	0.000327	CbGpPWpGaD
Bevantolol—ADRB1—GPCR downstream signaling—PIK3CB—prostate cancer	1.68e-05	0.000326	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—ITPR1—prostate cancer	1.66e-05	0.000322	CbGpPWpGaD
Bevantolol—ADRB2—GPCR downstream signaling—PIK3CB—prostate cancer	1.64e-05	0.000319	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—IGF1R—prostate cancer	1.62e-05	0.000315	CbGpPWpGaD
Bevantolol—ADRB1—GPCR downstream signaling—CXCL8—prostate cancer	1.62e-05	0.000313	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling by GPCR—PIK3CG—prostate cancer	1.61e-05	0.000312	CbGpPWpGaD
Bevantolol—ADRB1—Signaling by GPCR—JAK2—prostate cancer	1.61e-05	0.000312	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—CASP9—prostate cancer	1.59e-05	0.000309	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—IGF1R—prostate cancer	1.59e-05	0.000308	CbGpPWpGaD
Bevantolol—ADRB2—GPCR downstream signaling—CXCL8—prostate cancer	1.58e-05	0.000306	CbGpPWpGaD
Bevantolol—ADRB2—Signaling by GPCR—JAK2—prostate cancer	1.57e-05	0.000305	CbGpPWpGaD
Bevantolol—ADRA1A—GPCR downstream signaling—PIK3CD—prostate cancer	1.56e-05	0.000302	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—LPL—prostate cancer	1.56e-05	0.000302	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—NGFR—prostate cancer	1.54e-05	0.000299	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—PRKCQ—prostate cancer	1.54e-05	0.000299	CbGpPWpGaD
Bevantolol—ADRB1—GPCR downstream signaling—IL2—prostate cancer	1.54e-05	0.000299	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—PDGFRB—prostate cancer	1.54e-05	0.000299	CbGpPWpGaD
Bevantolol—ADRB1—Signaling by GPCR—PIK3CB—prostate cancer	1.53e-05	0.000296	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—MAP3K7—prostate cancer	1.53e-05	0.000296	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—LPL—prostate cancer	1.52e-05	0.000295	CbGpPWpGaD
Bevantolol—ADRB2—GPCR downstream signaling—IL2—prostate cancer	1.51e-05	0.000293	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—PDGFRB—prostate cancer	1.51e-05	0.000292	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—ITGB3—prostate cancer	1.5e-05	0.000291	CbGpPWpGaD
Bevantolol—ADRB2—Signaling by GPCR—PIK3CB—prostate cancer	1.49e-05	0.000289	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—ITGB3—prostate cancer	1.47e-05	0.000285	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—FGF10—prostate cancer	1.47e-05	0.000284	CbGpPWpGaD
Bevantolol—ADRB1—Signaling by GPCR—CXCL8—prostate cancer	1.47e-05	0.000284	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—ERBB3—prostate cancer	1.46e-05	0.000282	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—FGFR2—prostate cancer	1.46e-05	0.000282	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—ADRB2—prostate cancer	1.45e-05	0.000281	CbGpPWpGaD
Bevantolol—ADRB2—Signaling by GPCR—CXCL8—prostate cancer	1.44e-05	0.000278	CbGpPWpGaD
Bevantolol—ADRA1A—GPCR downstream signaling—JAK2—prostate cancer	1.43e-05	0.000278	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling by GPCR—MAP2K1—prostate cancer	1.43e-05	0.000276	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—ERBB3—prostate cancer	1.43e-05	0.000276	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—FGFR2—prostate cancer	1.42e-05	0.000276	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling by GPCR—PIK3CD—prostate cancer	1.42e-05	0.000275	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—VAV3—prostate cancer	1.42e-05	0.000274	CbGpPWpGaD
Bevantolol—ADRB1—Signaling by GPCR—IL2—prostate cancer	1.4e-05	0.000272	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—TERT—prostate cancer	1.4e-05	0.000271	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—TGFBR2—prostate cancer	1.4e-05	0.00027	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—ITPR1—prostate cancer	1.37e-05	0.000266	CbGpPWpGaD
Bevantolol—ADRB2—Signaling by GPCR—IL2—prostate cancer	1.37e-05	0.000266	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—TERT—prostate cancer	1.37e-05	0.000265	CbGpPWpGaD
Bevantolol—ADRA1A—GPCR downstream signaling—PIK3CB—prostate cancer	1.36e-05	0.000264	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—HIF1A—prostate cancer	1.34e-05	0.000259	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—IGF1R—prostate cancer	1.31e-05	0.000254	CbGpPWpGaD
Bevantolol—ADRA1A—GPCR downstream signaling—CXCL8—prostate cancer	1.31e-05	0.000253	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—HIF1A—prostate cancer	1.31e-05	0.000253	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—LEP—prostate cancer	1.3e-05	0.000253	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling by GPCR—JAK2—prostate cancer	1.3e-05	0.000252	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—CAV1—prostate cancer	1.29e-05	0.00025	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—KDR—prostate cancer	1.28e-05	0.000248	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—LEP—prostate cancer	1.28e-05	0.000247	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—CAV1—prostate cancer	1.26e-05	0.000245	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—LPL—prostate cancer	1.26e-05	0.000244	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—KDR—prostate cancer	1.25e-05	0.000242	CbGpPWpGaD
Bevantolol—ADRA1A—GPCR downstream signaling—IL2—prostate cancer	1.25e-05	0.000242	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—PDGFRB—prostate cancer	1.25e-05	0.000242	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—ESR1—prostate cancer	1.25e-05	0.000241	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling by GPCR—PIK3CB—prostate cancer	1.24e-05	0.000239	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—ESR1—prostate cancer	1.22e-05	0.000236	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—ITGB3—prostate cancer	1.22e-05	0.000236	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—BAD—prostate cancer	1.22e-05	0.000236	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—BAD—prostate cancer	1.19e-05	0.00023	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling by GPCR—CXCL8—prostate cancer	1.19e-05	0.00023	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—ERBB3—prostate cancer	1.18e-05	0.000229	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—FGFR2—prostate cancer	1.18e-05	0.000228	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—APC—prostate cancer	1.18e-05	0.000228	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—PIK3CG—prostate cancer	1.18e-05	0.000228	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—EGF—prostate cancer	1.16e-05	0.000225	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—IRS1—prostate cancer	1.16e-05	0.000225	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—PIK3CG—prostate cancer	1.15e-05	0.000223	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—APC—prostate cancer	1.15e-05	0.000223	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—IRS1—prostate cancer	1.14e-05	0.000221	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—EGF—prostate cancer	1.14e-05	0.000221	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling by GPCR—IL2—prostate cancer	1.13e-05	0.00022	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—TERT—prostate cancer	1.13e-05	0.000219	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—GSK3B—prostate cancer	1.13e-05	0.000219	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—INS—prostate cancer	1.11e-05	0.000216	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—GSK3B—prostate cancer	1.11e-05	0.000214	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—CREBBP—prostate cancer	1.09e-05	0.000211	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—INS—prostate cancer	1.09e-05	0.000211	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—HIF1A—prostate cancer	1.08e-05	0.000209	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—IGF1—prostate cancer	1.08e-05	0.000209	CbGpPWpGaD
Bevantolol—ADRB1—Signaling by GPCR—EGFR—prostate cancer	1.07e-05	0.000208	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—CREBBP—prostate cancer	1.07e-05	0.000207	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—LEP—prostate cancer	1.06e-05	0.000205	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—IGF1—prostate cancer	1.05e-05	0.000204	CbGpPWpGaD
Bevantolol—ADRB2—Signaling by GPCR—EGFR—prostate cancer	1.05e-05	0.000203	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—CAV1—prostate cancer	1.05e-05	0.000203	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—MAP2K1—prostate cancer	1.04e-05	0.000202	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—PIK3CD—prostate cancer	1.03e-05	0.000201	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—KDR—prostate cancer	1.03e-05	0.0002	CbGpPWpGaD
Bevantolol—ADRB1—GPCR downstream signaling—PIK3CA—prostate cancer	1.03e-05	0.000199	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—SERPINE1—prostate cancer	1.02e-05	0.000198	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—MAP2K1—prostate cancer	1.02e-05	0.000197	CbGpPWpGaD
Bevantolol—ADRB1—Signaling by GPCR—KRAS—prostate cancer	1.01e-05	0.000196	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—PIK3CD—prostate cancer	1.01e-05	0.000196	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—ESR1—prostate cancer	1.01e-05	0.000195	CbGpPWpGaD
Bevantolol—ADRB2—GPCR downstream signaling—PIK3CA—prostate cancer	1e-05	0.000194	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—SERPINE1—prostate cancer	1e-05	0.000194	CbGpPWpGaD
Bevantolol—ADRB2—Signaling by GPCR—KRAS—prostate cancer	9.91e-06	0.000192	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—FGF2—prostate cancer	9.91e-06	0.000192	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—BAD—prostate cancer	9.83e-06	0.000191	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—NOS3—prostate cancer	9.77e-06	0.000189	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—FGF2—prostate cancer	9.69e-06	0.000188	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—NOS3—prostate cancer	9.56e-06	0.000185	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—PIK3CG—prostate cancer	9.53e-06	0.000185	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—APC—prostate cancer	9.53e-06	0.000185	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—JAK2—prostate cancer	9.5e-06	0.000184	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—EGF—prostate cancer	9.42e-06	0.000182	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—IRS1—prostate cancer	9.42e-06	0.000182	CbGpPWpGaD
Bevantolol—ADRB1—Signaling by GPCR—PIK3CA—prostate cancer	9.31e-06	0.00018	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—JAK2—prostate cancer	9.29e-06	0.00018	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—MDM2—prostate cancer	9.27e-06	0.00018	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—ERBB2—prostate cancer	9.14e-06	0.000177	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—GSK3B—prostate cancer	9.14e-06	0.000177	CbGpPWpGaD
Bevantolol—ADRB2—Signaling by GPCR—PIK3CA—prostate cancer	9.11e-06	0.000176	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—MDM2—prostate cancer	9.07e-06	0.000176	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—PIK3CB—prostate cancer	9.02e-06	0.000175	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—INS—prostate cancer	9.02e-06	0.000175	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—ERBB2—prostate cancer	8.94e-06	0.000173	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—CREBBP—prostate cancer	8.83e-06	0.000171	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—PIK3CB—prostate cancer	8.82e-06	0.000171	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—IGF1—prostate cancer	8.72e-06	0.000169	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling by GPCR—EGFR—prostate cancer	8.68e-06	0.000168	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—CXCL8—prostate cancer	8.67e-06	0.000168	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—CXCL8—prostate cancer	8.48e-06	0.000164	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—CDKN1B—prostate cancer	8.47e-06	0.000164	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—MAP2K1—prostate cancer	8.43e-06	0.000163	CbGpPWpGaD
Bevantolol—ADRB1—GPCR downstream signaling—AKT1—prostate cancer	8.37e-06	0.000162	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—PIK3CD—prostate cancer	8.37e-06	0.000162	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—CASP3—prostate cancer	8.3e-06	0.000161	CbGpPWpGaD
Bevantolol—ADRA1A—GPCR downstream signaling—PIK3CA—prostate cancer	8.29e-06	0.000161	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—IL2—prostate cancer	8.28e-06	0.000161	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—SERPINE1—prostate cancer	8.28e-06	0.00016	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—CDKN1B—prostate cancer	8.28e-06	0.00016	CbGpPWpGaD
Bevantolol—ADRB1—Signaling by GPCR—IL6—prostate cancer	8.24e-06	0.00016	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling by GPCR—KRAS—prostate cancer	8.2e-06	0.000159	CbGpPWpGaD
Bevantolol—ADRB2—GPCR downstream signaling—AKT1—prostate cancer	8.19e-06	0.000159	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—CASP3—prostate cancer	8.12e-06	0.000157	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—IL2—prostate cancer	8.1e-06	0.000157	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—CCND1—prostate cancer	8.08e-06	0.000156	CbGpPWpGaD
Bevantolol—ADRB2—Signaling by GPCR—IL6—prostate cancer	8.06e-06	0.000156	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—FGF2—prostate cancer	8.02e-06	0.000155	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—CTNNB1—prostate cancer	8e-06	0.000155	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—NOS3—prostate cancer	7.91e-06	0.000153	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—CCND1—prostate cancer	7.9e-06	0.000153	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—MMP9—prostate cancer	7.84e-06	0.000152	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—CTNNB1—prostate cancer	7.82e-06	0.000152	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—CDKN1A—prostate cancer	7.81e-06	0.000151	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—PTEN—prostate cancer	7.79e-06	0.000151	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—JAK2—prostate cancer	7.68e-06	0.000149	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—MMP9—prostate cancer	7.67e-06	0.000149	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—CDKN1A—prostate cancer	7.64e-06	0.000148	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—PTEN—prostate cancer	7.62e-06	0.000148	CbGpPWpGaD
Bevantolol—ADRB1—Signaling by GPCR—AKT1—prostate cancer	7.6e-06	0.000147	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling by GPCR—PIK3CA—prostate cancer	7.53e-06	0.000146	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—MDM2—prostate cancer	7.5e-06	0.000145	CbGpPWpGaD
Bevantolol—ADRB2—Signaling by GPCR—AKT1—prostate cancer	7.44e-06	0.000144	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—EP300—prostate cancer	7.43e-06	0.000144	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—ERBB2—prostate cancer	7.4e-06	0.000143	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—PIK3CB—prostate cancer	7.3e-06	0.000141	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—EP300—prostate cancer	7.27e-06	0.000141	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—SRC—prostate cancer	7.23e-06	0.00014	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—SRC—prostate cancer	7.07e-06	0.000137	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—VEGFA—prostate cancer	7.04e-06	0.000136	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—CXCL8—prostate cancer	7.01e-06	0.000136	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—STAT3—prostate cancer	6.97e-06	0.000135	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—VEGFA—prostate cancer	6.89e-06	0.000133	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—CDKN1B—prostate cancer	6.85e-06	0.000133	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—STAT3—prostate cancer	6.82e-06	0.000132	CbGpPWpGaD
Bevantolol—ADRA1A—GPCR downstream signaling—AKT1—prostate cancer	6.78e-06	0.000131	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—CASP3—prostate cancer	6.71e-06	0.00013	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—IL2—prostate cancer	6.7e-06	0.00013	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling by GPCR—IL6—prostate cancer	6.67e-06	0.000129	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—CCND1—prostate cancer	6.53e-06	0.000127	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—MYC—prostate cancer	6.48e-06	0.000126	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—CTNNB1—prostate cancer	6.47e-06	0.000125	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—TGFB1—prostate cancer	6.46e-06	0.000125	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—MMP9—prostate cancer	6.34e-06	0.000123	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—MYC—prostate cancer	6.34e-06	0.000123	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—EGFR—prostate cancer	6.34e-06	0.000123	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—CDKN1A—prostate cancer	6.32e-06	0.000122	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—TGFB1—prostate cancer	6.32e-06	0.000122	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—PTEN—prostate cancer	6.31e-06	0.000122	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—EGFR—prostate cancer	6.2e-06	0.00012	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling by GPCR—AKT1—prostate cancer	6.15e-06	0.000119	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—EP300—prostate cancer	6.01e-06	0.000117	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—KRAS—prostate cancer	5.99e-06	0.000116	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—KRAS—prostate cancer	5.85e-06	0.000113	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—SRC—prostate cancer	5.85e-06	0.000113	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—VEGFA—prostate cancer	5.7e-06	0.00011	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—STAT3—prostate cancer	5.64e-06	0.000109	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—PIK3CA—prostate cancer	5.5e-06	0.000107	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—PIK3CA—prostate cancer	5.38e-06	0.000104	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—TP53—prostate cancer	5.32e-06	0.000103	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—MYC—prostate cancer	5.24e-06	0.000102	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—TGFB1—prostate cancer	5.23e-06	0.000101	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—TP53—prostate cancer	5.2e-06	0.000101	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—EGFR—prostate cancer	5.13e-06	9.93e-05	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—IL6—prostate cancer	4.87e-06	9.43e-05	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—KRAS—prostate cancer	4.84e-06	9.38e-05	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—IL6—prostate cancer	4.76e-06	9.23e-05	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—AKT1—prostate cancer	4.49e-06	8.7e-05	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—PIK3CA—prostate cancer	4.45e-06	8.62e-05	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—AKT1—prostate cancer	4.39e-06	8.51e-05	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—TP53—prostate cancer	4.3e-06	8.34e-05	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—IL6—prostate cancer	3.94e-06	7.63e-05	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—AKT1—prostate cancer	3.63e-06	7.04e-05	CbGpPWpGaD
